Education:

Ph.D. University of Louisville, Kentucky 1988
Ph.D. Utkal University, India 1978
M.S. Calcutta University, India 1971
B.S. Calcutta University 1969

Research Interests: My research is centered on the development of organometallic anticancer drugs, sensors, and material science.

Research Gate: https://www.researchgate.net/profile/Santosh_Mandal6

Selected Publications:  (h-index 13, i10-index 18, citations 490)

• Stevenson M, Banerjee HN, Banerjee N, Rawat K, Chen L, Worthington M, Hodge S, Walker R, Verma M, Sarkar F, Mandal S (2020). A health disparities study of MicroRNA-146a expression in prostate cancer samples derived from African American and European American patients. J. Solid Tumors 10(2): 1-6. DOI: 10.5430/jst.v10n2p1
• Banerjee H, Krauss C, Worthington M, Banerjee N, Walker RS, Hodges S, Chen L, Rawat K, Dasgupta S, Ghosh S, Mandal S (2019). Differential expression of efferocytosis and phagocytosis associated genes in tumor associated macrophages exposed to African American patient derived prostate cancer microenvironment. J Solid Tumors 9(2): 22-27.
• Wilder PT, Weber DJ, Winstead A, Parnell S, Hinton TV, Stevenson M, Giri D, Azemati S, Olczak P, Powell BV, Odebode T, Tadesse S, Zhang Y, Pramanik SK, Wachira JM, Ghimire S, McCarthy P, Barfield A, Banerjee HN, Chen C, Golen JA, Rheingold AL, Krause JA, Ho DM, Zavalij PY, Shaw R, Mandal SK (2018). Unprecedented anticancer activities of organorhenium sulfonate and carboxylato complexes against hormone-dependent MCF-7 and hormone-independent triple-negative MDA-MB-231 breast cancer cells. Mol Cell Biochem 441:151-163.
• Banerjee HN, Vaughan D, Boston A, Thorne G, Payne G, Sampson J, Manglik V, Olczak P, Powell BV, Winstead A, Shaw R, Mandal SK (2018). The Effects of Synthesized Rhenium Acetylsalicylate Compounds on Human Astrocytoma Cell Lines. J Cancer Sci Ther 10(2): 512.
• Banerjee HN, Boston A, Barfield A, Stevenson M, Sarkar FH, Giri D, Winstead A, Kause JA, Mandal SK (2016). A Study of the Effects of Novel Rhenium Compounds on Pancreatic and Prostate Cancer Cell Lines. Int J Sci Res 5(7): 481-483.
• Medley J, Payne G, Banerjee HN, Giri D, Winstead A, Wachira JM, Krause, JA, Shaw R, Pramanik SK, Mandal SK (2015). DNA-Binding and Cytotoxic Efficacy Studies of Organorhenium Pentylcarbonate Compounds. Mol Cell Biochem 398(1-2): 21-30.
• Parson C, Smith V, Krauss C, Banerjee HN, Reilly C, Krause JA, Wachira JM, Giri D, Winstead A, Mandal SK (2014). Anticancer Properties of Novel Rhenium Pentylcarbonato Compounds against MDA-MB-468 (HTB-132) Triple Node Negative Human Breast Cancer Cell Lines. Brit J Pharmaceut Res 4(3): 362-367.
• Parson C, Smith V, Krauss C, Banerjee HN, Reilly C, Krause JA, Wachira JM, Giri D, Winstead A, Mandal SK. (2013). The effect of novel rhenium compounds on lymphosarcoma, PC-3 prostate and myeloid leukemia cancer cell lines and an investigation on the DNA binding properties of one of these compounds through electronic spectroscopy. J Bioproces Biotechniq 4(1):1-5.
• Mbagu MK, Kebulu DN, Winstead A, Pramanik SK, Banerjee HN, Iwunze MO, Wachira JM, Greco GE, Haynes GK, Sehmer A, Sarkar FH, Ho DM, Pike RD, Mandal SK (2012). Fac-tricarbonyl(pentylcarbonato)(α-diimine)rhenium complexes: One-pot synthesis, characterization, fluorescence studies, and cytotoxic activity against human MDA-MB-231 breast, CCl-227 colon and BxPC-3 pancreatic carcinoma cell lines. Inorg Chem Commun 21: 35-38.